Response to: Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al

Yoshiya Tanaka; Koji Oba; Tsutomu Takeuchi

doi:10.1136/annrheumdis-2019-216593

Response to: Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al

Yoshiya Tanaka, Koji Oba, Tsutomu Takeuchi

Vice-President

Research output: Contribution to journal › Letter

Original language	English
Journal	Annals of the rheumatic diseases
DOIs	https://doi.org/10.1136/annrheumdis-2019-216593
Publication status	Accepted/In press - 2019 Jan 1

Keywords

DMARDs (biological)
rheumatoid arthritis
treatment

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1136/annrheumdis-2019-216593

Cite this

Tanaka, Y., Oba, K., & Takeuchi, T. (Accepted/In press). Response to: Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al. Annals of the rheumatic diseases. https://doi.org/10.1136/annrheumdis-2019-216593

Response to : Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al. / Tanaka, Yoshiya; Oba, Koji; Takeuchi, Tsutomu.

In: Annals of the rheumatic diseases, 01.01.2019.

Research output: Contribution to journal › Letter

Tanaka, Y, Oba, K & Takeuchi, T 2019, 'Response to: Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al', Annals of the rheumatic diseases. https://doi.org/10.1136/annrheumdis-2019-216593

Tanaka Y, Oba K, Takeuchi T. Response to: Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al. Annals of the rheumatic diseases. 2019 Jan 1. https://doi.org/10.1136/annrheumdis-2019-216593

@article{d1344b945b194934abe62c8c0e49ec2b,

title = "Response to: {\^A} € Comment on {\^a} € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al",

keywords = "DMARDs (biological), rheumatoid arthritis, treatment",

author = "Yoshiya Tanaka and Koji Oba and Tsutomu Takeuchi",

year = "2019",

month = jan,

day = "1",

doi = "10.1136/annrheumdis-2019-216593",

language = "English",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Response to

T2 - Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al

AU - Tanaka, Yoshiya

AU - Oba, Koji

AU - Takeuchi, Tsutomu

PY - 2019/1/1

Y1 - 2019/1/1

KW - DMARDs (biological)

KW - rheumatoid arthritis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85076475249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076475249&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2019-216593

DO - 10.1136/annrheumdis-2019-216593

M3 - Letter

C2 - 31818809

AN - SCOPUS:85076475249

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -